197 related articles for article (PubMed ID: 23673926)
21. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
22. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M
Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
24. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.
Burel SA; Harakawa N; Zhou L; Pabst T; Tenen DG; Zhang DE
Mol Cell Biol; 2001 Aug; 21(16):5577-90. PubMed ID: 11463839
[TBL] [Abstract][Full Text] [Related]
25. The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor.
Hiebert SW; Reed-Inderbitzin EF; Amann J; Irvin B; Durst K; Linggi B
Blood Cells Mol Dis; 2003; 30(2):177-83. PubMed ID: 12732181
[TBL] [Abstract][Full Text] [Related]
26. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
27. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
[TBL] [Abstract][Full Text] [Related]
30. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
31. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.
Hines R; Boyapati A; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):297-306. PubMed ID: 17590361
[TBL] [Abstract][Full Text] [Related]
32. The AML1/ETO fusion protein activates transcription of BCL-2.
Klampfer L; Zhang J; Zelenetz AO; Uchida H; Nimer SD
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14059-64. PubMed ID: 8943060
[TBL] [Abstract][Full Text] [Related]
33. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
34. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic consequences of AML1-ETO action at the human c-FMS locus.
Follows GA; Tagoh H; Lefevre P; Hodge D; Morgan GJ; Bonifer C
EMBO J; 2003 Jun; 22(11):2798-809. PubMed ID: 12773394
[TBL] [Abstract][Full Text] [Related]
36. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal.
Tonks A; Tonks AJ; Pearn L; Pearce L; Hoy T; Couzens S; Fisher J; Burnett AK; Darley RL
Leukemia; 2004 Jul; 18(7):1238-45. PubMed ID: 15152269
[TBL] [Abstract][Full Text] [Related]
37. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
38. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
Gardini A; Cesaroni M; Luzi L; Okumura AJ; Biggs JR; Minardi SP; Venturini E; Zhang DE; Pelicci PG; Alcalay M
PLoS Genet; 2008 Nov; 4(11):e1000275. PubMed ID: 19043539
[TBL] [Abstract][Full Text] [Related]
39. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]